Heart failure & cardiomyopathies
Implementation of guideline-recommended therapies in heart failure with reduced ejection fraction according to heart failure duration: An analysis of 55 581 patients from the Swedish Heart Failure (SwedeHF) Registry
Authors' conclusion
Most patients received RASI and beta-blockers in the first months following HFrEF diagnosis. Use of ARNI, MRA and SGLT2i was limited, both in the early and later time periods.
Study context
- Population
- Patients with HFrEF (EF <40%) in the Swedish Heart Failure (HF) Registry, 2000–2021
- Participants
- 55,581 patients
- Exposure
- GDMT use by HF duration
- Outcome
- Use of guideline-recommended therapies (renin-angiotensin system inhibitors (RASI)/angiotensin receptor-neprilysin inhibitors (ARNI), beta-blockers, mineralocorticoid receptor antagonists (MRA), SGLT2i) by time from HF diagnosis
Methodological detailsnationwide registry linked to national registries
- Nationwide registry linked to national registries
Main finding
As reported in the abstract
Use of guideline-recommended therapies by HF duration
Use of guideline-recommended therapies by HF duration
RASI or ARNI
ARNI alone
MRA
Beta-blockers
SGLT2i
CRT/ICD >12 months 18%
Observational data: associations, not effects.
Further findings
Patient characteristics by HF duration
- Shorter HF duration: younger, lower NYHA class, fewer CV comorbidities
Original publication
Implementation of guideline-recommended therapies in heart failure with reduced ejection fraction according to heart failure duration: An analysis of 55 581 patients from the Swedish Heart Failure (SwedeHF) Registry. Eur J Heart Fail. Published 9 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →